Our Mission

Our mission at Pax Neuroscience is to incorporate the biology of depression in the design of agents to improve and transform the standard of care for clinical depression and related mood disorders.

Pax's technology platform analyzes the biology of depression and mood disorders, and the mechanism of action of antidepressants to inform decisions of patients and physicians about the diagnosis and treatment of depression, as well as to improve antidepressant drug development.

MoodMarkDX® and MoodMarkRX® are the first evidence-based tests to provide unbiased, biological evidence of depression diagnosis and treatment-response prediction derived from physiological changes specific to clinical depression. U.S. and international patents protect Pax's biomarker assays for antidepressant drug development and Pax's blood tests.